Skip to content

ELASMOGEN

discovering and developing soloMERs for the treatment of auto-immune mediated, inflammatory diseases

ELASMOGEN
  • about
    • the team
    • the board
    • investors
  • soloMER technology
    • discovery platform
    • product development options
  • pipeline
    • auto-Immune / anti-Inflammatory
    • oncology
    • NDURE programme
  • partners
    • licensing
    • partnerships and collaborations
  • news
    • press release
    • publications
    • events
  • contact
Elasmogen Ltd wins the “Perfect Pitch” at BioTrinity 2016

News

  • Home
  • 2016
  • March
  • Press release
  • Publications
  • Events

News archives

  • March 2023
  • September 2022
  • August 2022
  • May 2022
  • December 2021
  • September 2021
  • January 2021
  • December 2020
  • July 2020
  • May 2020
  • April 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • July 2019
  • May 2019
  • March 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • August 2018
  • May 2018
  • January 2018
  • November 2017
  • May 2017
  • March 2017
  • January 2017
  • July 2016
  • March 2016

Month: March 2016

Elasmogen Ltd wins the “Perfect Pitch” at BioTrinity 2016 | 27.03.2016

Aberdeen, UK – [27th March 2016] As Europe’s leading biopartnering and investment conference, BioTrinity brings together investors, pharmaceutical executives and innovative life science R&D companies, from around the world. To mark BioTrinity’s 10th anniversary the new Perfect Pitch session has been introduced to their London meeting to increase the number of ways biotechnology companies can […]

ELASMOGEN Copyright 2023

Liberty Building | Foresterhill Health Campus | Aberdeen | AB25 2ZP

  • info@elasmogen.com
  • twitter
  • linkedin